Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft
Antonini, Teresa M.a,b,c,k; Furlan, Valeried,k; Teicher, Elinaa,e,k; Haim-Boukobza, Stephanieb,c,f,k; Sebagh, Myleneb,c,g,k; Coilly, Audreya,b,c,k; Bonhomme-Faivre, Laurenceh,k; Peytavin, Gillesi,j; Roque-Afonso, Anne-Marieb,c,f,k; Vittecoq, Daniele,k; Samuel, Didiera,b,c,k; Taburet, Anne-Maried,k; Duclos-Vallée, Jean-Charlesa,b,c,k
We report, for the first time, the outcome of anti-hepatitis C virus (HCV) triple therapy with telaprevir in an HIV/HCV co-infected transplanted patient. After liver transplantation, the patient experienced a severe HCV recurrence with fibrosing cholestatic hepatitis, and anti-HCV therapy with pegylated interferon alpha 2a, ribavirin and telaprevir was initiated. A sustained virological response was achieved after 48 weeks of anti-HCV therapy. Drug–drug interactions between antiretroviral therapy, immunosuppressive agents and anti-HCV therapy could be managed.
© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins